{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T01:09:21Z","timestamp":1774314561363,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06861-0","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T03:11:52Z","timestamp":1770779512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Guided by target selection, inotuzumab ozogamicin successfully salvaged a patient with refractory follicular lymphoma after anti-CD19 and anti-CD22 CAR T-cell therapy: a case report and literature review"],"prefix":"10.1007","volume":"105","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuquan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-4953","authenticated-orcid":false,"given":"Qi","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"19","key":"6861_CR1","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A et al (2023) Five-year follow-up of ZUMA-1 supports the curative potential of Axicabtagene Ciloleucel in refractory large B-cell lymphoma. Blood 141(19):2307\u20132315. https:\/\/doi.org\/10.1182\/blood.2022018893","journal-title":"Blood"},{"issue":"7","key":"6861_CR2","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA et al (2022) Axicabtagene Ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med 386(7):640\u2013654. https:\/\/doi.org\/10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"issue":"7","key":"6861_CR3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1056\/NEJMc2030164","volume":"384","author":"EA Chong","year":"2021","unstructured":"Chong EA, Ruella M, Schuster SJ (2021) Five-Year outcomes for refractory B-Cell lymphomas with CAR T-Cell therapy. N Engl J Med 384(7):673\u2013674. https:\/\/doi.org\/10.1056\/NEJMc2030164","journal-title":"N Engl J Med"},{"issue":"1","key":"6861_CR4","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2141.2009.07701.x","volume":"146","author":"A Takeshita","year":"2009","unstructured":"Takeshita A, Shinjo K, Yamakage N et al (2009) CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 146(1):34\u201343. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07701.x","journal-title":"Br J Haematol"},{"issue":"2","key":"6861_CR5","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124(2):188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"issue":"4","key":"6861_CR6","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"6861_CR7","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1182\/blood.2020006245","volume":"137","author":"JY Spiegel","year":"2021","unstructured":"Spiegel JY, Dahiya S, Jain MD et al (2021) Outcomes of patients with large B-cell lymphoma progressing after Axicabtagene Ciloleucel therapy. Blood 137(13):1832\u20131835. https:\/\/doi.org\/10.1182\/blood.2020006245","journal-title":"Blood"},{"issue":"8","key":"6861_CR8","doi-asserted-by":"publisher","first-page":"E209","DOI":"10.1002\/ajh.25505","volume":"94","author":"VA Chow","year":"2019","unstructured":"Chow VA, Gopal AK, Maloney DG et al (2019) Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy. Am J Hematol 94(8):E209\u2013e213. https:\/\/doi.org\/10.1002\/ajh.25505","journal-title":"Am J Hematol"},{"issue":"5","key":"6861_CR9","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/curroncol32050285","volume":"32","author":"M Castonguay","year":"2025","unstructured":"Castonguay M, Roy J, Claveau JS et al (2025) Allogeneic hematopoietic cell transplant for B-Cell lymphomas in the era of novel cellular therapies: experience from a tertiary Canadian center. Curr Oncol 32(5):285. https:\/\/doi.org\/10.3390\/curroncol32050285","journal-title":"Curr Oncol"},{"issue":"3","key":"6861_CR10","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/j.1365-2567.2007.02752.x","volume":"123","author":"J Walker","year":"2008","unstructured":"Walker J, Smith A (2008) K <>G CD22: an inhibitory enigma. Immunology 123 3 314\u2013325 https:\/\/doi.org\/10.1111\/j.1365-2567.2007.02752.x","journal-title":"Immunology"},{"issue":"20","key":"6861_CR11","doi-asserted-by":"publisher","first-page":"6417","DOI":"10.1158\/1078-0432.Ccr-11-0486","volume":"17","author":"AD Ricart","year":"2011","unstructured":"Ricart AD (2011) Antibody-drug conjugates of Calicheamicin derivative: Gemtuzumab Ozogamicin and inotuzumab Ozogamicin. Clin Cancer Res 17(20):6417\u20136427. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0486","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6861_CR12","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1365-2141","volume":"146","author":"A Takeshita","year":"2009","unstructured":"Takeshita A, Shinjo K, Yamakage N et al (2009) CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br J Haematol 146(1):34\u201343. https:\/\/doi.org\/10.1111\/j.1365-21412009.07701. x","journal-title":"Br J Haematol"},{"issue":"12","key":"6861_CR13","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1200\/JCO.2009.25.1900","volume":"28","author":"A Advani","year":"2010","unstructured":"Advani A, Coiffier B, Czuczman MS et al (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel Immunoconjugate for the treatment of B-cell non-Hodgkin\u2019s lymphoma: results of a phase I study. J Clin Oncol 28(12):2085\u20132093. https:\/\/doi.org\/10.1200\/JCO.2009.25.1900","journal-title":"J Clin Oncol"},{"issue":"2","key":"6861_CR14","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/hep.30222","volume":"69","author":"GB McDonald","year":"2019","unstructured":"McDonald GB, Freston JW, Boyer JL et al (2019) Liver complications following treatment of hematologic malignancy with Anti-CD22-Calicheamicin (Inotuzumab Ozogamicin). Hepatology 69(2):831\u2013844. https:\/\/doi.org\/10.1002\/hep.30222","journal-title":"Hepatology"},{"issue":"4","key":"6861_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","volume":"53","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P, Cutler C, de Lima M et al (2018) Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transpl 53(4):449\u2013456. https:\/\/doi.org\/10.1038\/s41409-017-0019-y","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"6861_CR16","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375(8):740\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1509277","journal-title":"N Engl J Med"},{"issue":"3","key":"6861_CR17","doi-asserted-by":"publisher","first-page":"e227","DOI":"10.1016\/j.clml.2020.12.008","volume":"21","author":"X Li","year":"2021","unstructured":"Li X, Zhou M, Qi J et al (2021) Efficacy and safety of inotuzumab Ozogamicin (CMC-544) for the treatment of Relapsed\/Refractory acute lymphoblastic leukemia and Non-Hodgkin lymphoma: A systematic review and Meta-Analysis. Clin Lymphoma Myeloma Leuk 21(3):e227\u2013e247. https:\/\/doi.org\/10.1016\/j.clml.2020.12.008","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6861_CR18","doi-asserted-by":"publisher","unstructured":"Wu XJ, Shao ZH (2015) Recent advances of researches on expression, function and regulation of CD22. Zhongguo shi yan xue ye xue za zhi 23(2):573\u2013577. https:\/\/doi.org\/10.7534\/j.issn.1009-2137.2015.02.054","DOI":"10.7534\/j.issn.1009-2137.2015.02.054"},{"issue":"1","key":"6861_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1080\/21556660.2017.1315336","volume":"6","author":"R Sangha","year":"2017","unstructured":"Sangha R, Davies A, Dang NH et al (2017) Phase 1 study of inotuzumab Ozogamicin combined with R-GDP for the treatment of patients with relapsed\/refractory CD22\u2009+\u2009B-cell non-Hodgkin lymphoma. J Drug Assess 6(1):10\u201317. https:\/\/doi.org\/10.1080\/21556660.2017.1315336","journal-title":"J Drug Assess"},{"issue":"5","key":"6861_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/jco.2012.42.7211","volume":"31","author":"L Fayad","year":"2013","unstructured":"Fayad L, Offner F, Smith MR et al (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I\/II study evaluating the Immunoconjugate inotuzumab Ozogamicin with rituximab. J Clin Oncol 31(5):573\u2013583. https:\/\/doi.org\/10.1200\/jco.2012.42.7211","journal-title":"J Clin Oncol"},{"issue":"5","key":"6861_CR21","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/j.1349-7006.2012.02241.x","volume":"103","author":"M Ogura","year":"2012","unstructured":"Ogura M, Hatake K, Ando K et al (2012) Phase I study of anti-CD22 Immunoconjugate inotuzumab Ozogamicin plus rituximab in relapsed\/refractory B-cell non-Hodgkin lymphoma. Cancer Sci 103(5):933\u2013938. https:\/\/doi.org\/10.1111\/j.1349-7006.2012.02241.x","journal-title":"Cancer Sci"},{"issue":"19","key":"6861_CR22","doi-asserted-by":"publisher","first-page":"4807","DOI":"10.1158\/1078-0432.Ccr-15-2488","volume":"22","author":"M Ogura","year":"2016","unstructured":"Ogura M, Tobinai K, Hatake K et al (2016) Phase I study of inotuzumab Ozogamicin combined with R-CVP for Relapsed\/Refractory CD22\u2009+\u2009B-cell Non-Hodgkin lymphoma. Clin Cancer Res 22(19):4807\u20134816. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-15-2488","journal-title":"Clin Cancer Res"},{"issue":"4","key":"6861_CR23","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/bjh.14094","volume":"174","author":"A Goy","year":"2016","unstructured":"Goy A, Forero A, Wagner-Johnston N et al (2016) A phase 2 study of inotuzumab Ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. Br J Haematol 174(4):571\u2013581. https:\/\/doi.org\/10.1111\/bjh.14094","journal-title":"Br J Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06861-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06861-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:03:32Z","timestamp":1771949012000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06861-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["6861"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06861-0","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"24 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the Department of Hematology, Tianjin First Center Hospital (Tianjin, China). (Approved No. of ethic committee: 2018N105KY and 2015002X).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Written informed consent was obtained from a legally authorized representative for anonymized patient information to be published in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}